Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Signs Coverage Agreement With Blue Cross Blue Shield of Minnesota

NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield (BCBS) of Minnesota to provide access to its cancer diagnostics and genomic testing services to the healthcare network's 2.6 million members.

BCBS Minnesota is the largest health plan in the state, the company said in a statement.

The company signed several similar coverage agreements in 2015 with various insurance providers, including BCBS Illinois in September to cover 7.3 million people, and with with BCBS North Carolina, BCBS Nebraska, and WellMark in November to cover a total of 6.7 million people. CGI said it now has contracts with 29 payers covering 180 million lives across commercial Medicare advantage and Medicaid plans.

"We are looking forward to offering our comprehensive portfolio of oncology diagnostic tests to help Minnesotans have the most effective and high-quality personalized cancer care available," Randy Goodman, Cancer Genetics' director of reimbursement and clinical revenue cycle management, said in a statement."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.